In a head-to-head trial of teriparatide versus risedronate in 1,360 post-menopausal women with severe osteoporosis (defined as having two moderate or one severe vertebral fractures and a bone mineral density T score of −1 or less), new vertebral fractures occurred in 5.4% of women taking teriparatide compared with 12% of those taking risedronate (P < 0.0001). Incidences of clinical fractures (P = 0.0009) were also reduced in the teriparatide group compared with the risedronate group.
References
Kendler, D. L. et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32137-2 (2017)
Rights and permissions
About this article
Cite this article
Collison, J. Teriparatide preferable for fracture prevention. Nat Rev Rheumatol 14, 4 (2018). https://doi.org/10.1038/nrrheum.2017.194
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.194